Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
Keith C HayesDepartment of Physical Medicine and Rehabilitation, The University of Western Ontario, London, ON, CanadaAbstract: Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K+) channel-blocking compounded dalfampridine, also known as fampridine, and chemically&a...
Guardado en:
Autor principal: | Hayes KC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ca611cb145b34bab91b18fb7e442dcf5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara M, et al.
Publicado: (2013) -
Walking impairment in patients with multiple sclerosis: exercise training as a treatment option
por: Robert W Motl, et al.
Publicado: (2010) -
The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens J
Publicado: (2011) -
Role of extended release quetiapine in the management of bipolar disorders
por: Rayan K Al Jurdi, et al.
Publicado: (2010) -
Management of obsessive-compulsive disorder with fluvoxamine extended release
por: Lídia Ordacgi, et al.
Publicado: (2009)